Programs
DELIVERING THE FUTURE OF GENE THERAPY
AVB-101
Our lead program, AVB-101 is an investigational gene therapy being developed for people living with frontotemporal dementia with GRN mutations (FTD-GRN), in Phase 1/2 clinical trial in UK, Europe, USA, and Canada.
Partnered with
AVB-307
An intravitreally delivered optogenetic investigational gene therapy for the treatment of retinal dystrophies in clinic for retinitis pigmentosa and geographic atrophy.
Partnered with
AVB-406
vMiX proprietary RNA gene silencing platform and novel BBB-crossing capsids being developed to target Alzheimer’s disease and other tauopathies.
Wholly owned
Science and Innovation
Find out what makes AviadoBio’s technology platform stand out from Alex Bloom, Chief Technology Officer.
PRECLINICAL PIPELINE
AviadoBio’s proprietary platforms, including intrathalamic and vMiX™ RNA silencing system, plus expertise in intravitreal, and blood-brain barrier (BBB)-penetrant delivery approaches, enable precise, durable therapeutic expression across complex neural systems such as the brain and retina.
Our genetic medicines are uniquely developed with three levels of precision – payload, target, and delivery – engineered together for maximum therapeutic benefit.
FRONTOTEMPORAL DEMENTIA
Frontotemporal dementia (FTD) is a devastating form of early-onset dementia and is characterized by a rapid decline in executive function, behavior and/or language, and typically leads to death within seven to 13 years of symptom onset and three to 10 years from diagnosis.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig’s disease, is a devastating multisystem neurodegenerative disease. ALS is primarily characterized by degeneration of both upper and lower motor neurons.
Retinitis Pigmentosa
Retinitis Pigmentosa (RP) is a leading cause of visual disability and blindness, affecting over 1.5 million people worldwide. Progressive symptoms include night blindness, reduction in peripheral and central vision, commonly called “tunnel vision,” and reduced ability to see details and colors.
Alzheimer’s disease and other tauopathies
Alzheimer’s disease and other tauopathies are a group of progressive brain disorders characterized by abnormal changes in tau, a protein that normally supports and stabilizes neurons. In these conditions, tau becomes dysfunctional, clumps together, and disrupts communication between brain cells, ultimately leading to cognitive decline, memory loss, and changes in behavior or movement.